Expression of galectin-9 and CTLA-4 as potential biomarkers in ovarian cancer: Their association with histological subtypes and disease stage
نویسندگان
doi
10.48309/jmpcr.2025.509532.1618چکیده
Ovarian cancer is the second leading cause of gynecologic cancer-related deaths worldwide, with its high mortality rate largely attributed to late-stage detection and tumor heterogeneity. Recent evidence suggests that immune-related biomarkers, including Galectin-9 and CTLA-4, play a critical role in cancer progression and may serve as potential prognostic and therapeutic targets. This research investigated the expression levels of Galectin-9 and CTLA-4 in High-Grade Serous Ovarian Cancer (HGSOC) and Low-Grade Serous Ovarian Cancer (LGSOC), exploring their correlation with tumor stage and CA 125 levels. A retrospective cross-sectional study was conducted on ovarian cancer patients at Dr. Soetomo General Hospital, Surabaya, from 2021 to 2023. Immunohistochemical analysis was performed on 50 paraffin-embedded tissue samples to assess biomarker expression. Chi-Square statistical analysis identified a significant difference in Galectin-9 expression between HGSOC and LGSOC (p = 0.0485). Similarly, CTLA-4 expression showed a highly significant difference between these subtypes (p = 0.0000021). Furthermore, a significant association was observed between CTLA-4 expression and tumor stage (p = 0.000229), suggesting its role in disease progression. However, no notable association was identified between the expression of either biomarker and CA 125 levels. These findings suggest that Galectin-9 and CTLA-4 may serve as valuable biomarkers for distinguishing ovarian cancer subtypes and assessing disease progression, particularly in HGSOC. Further large-scale studies and functional analyses are warranted to explore their potential roles in prognosis and response to immunotherapy.